Literature DB >> 34071338

Application of Immunohistochemistry in the Pathological Diagnosis of Liver Tumors.

Yoshihisa Takahashi1, Erdenetsogt Dungubat1,2, Hiroyuki Kusano1, Dariimaa Ganbat3, Yasuhiko Tomita1, Sarandelger Odgerel4, Toshio Fukusato5.   

Abstract

Although radiological diagnostics have been progressing, pathological diagnosis remains the most reliable method for diagnosing liver tumors. In some cases, definite pathological diagnosis cannot be obtained by histological evaluation alone, especially when the sample is a small biopsy; in such cases, immunohistochemical staining is very useful. Immunohistochemistry is the most frequently used technique for molecular pathological diagnosis due to its broad application, ease of performance and evaluation, and reasonable cost. The results occasionally reflect specific genetic mutations. The immunohistochemical markers of hepatocellular carcinoma include those of hepatocellular differentiation-such as hepatocyte paraffin 1 and arginase-1-and those of malignant hepatocytes-such as glypican-3, heat shock protein 70, and glutamine synthetase (GS). To classify the subtypes of hepatocellular adenoma, examination of several immunohistochemical markers, such as liver fatty acid-binding protein, GS, and serum amyloid A, is indispensable. Immunohistochemical staining for GS is also important for the diagnosis of focal nodular hyperplasia. The representative immunohistochemical markers of intrahepatic cholangiocarcinoma include cytokeratin (CK) 7 and CK19. In this article, we provide an overview of the application of immunohistochemistry in the pathological diagnosis of liver tumors referring to the association with genetic alterations. Furthermore, we aimed to explain the practical points in the differential diagnosis of liver tumors by immunohistochemical staining.

Entities:  

Keywords:  focal nodular hyperplasia; hepatocellular adenoma; hepatocellular carcinoma; immunohistochemical staining; intrahepatic cholangiocarcinoma; liver tumor

Year:  2021        PMID: 34071338     DOI: 10.3390/ijms22115780

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  86 in total

1.  Carcinoma, a fibrolamellar variant--immunohistochemical analysis of 4 cases.

Authors:  Barbara Górnicka; Bogna Ziarkiewicz-Wróblewska; Tadeusz Wróblewski; Grzegorz Marek Wilczynski; Lukasz Koperski; Marek Krawczyk; Aleksander Wasiutynski
Journal:  Hepatogastroenterology       Date:  2005 Mar-Apr

2.  C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis.

Authors:  Yi-Chen Yeh; Hao-Jan Lei; Ming-Huang Chen; Hsiang-Ling Ho; Ling-Ya Chiu; Chung-Pin Li; Yu-Chao Wang
Journal:  Am J Surg Pathol       Date:  2017-12       Impact factor: 6.394

3.  cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.

Authors:  S Y Xiao; H L Wang; J Hart; D Fleming; M R Beard
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

4.  Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms.

Authors:  Benjamin C Yan; Can Gong; Jie Song; Thomas Krausz; Maria Tretiakova; Elizabeth Hyjek; Hikmat Al-Ahmadie; Venancio Alves; Shu-Yuan Xiao; Robert A Anders; John A Hart
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

5.  Integrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma.

Authors:  Yurie Soejima; Masafumi Inoue; Yoshihisa Takahashi; Hiroshi Uozaki; Motoji Sawabe; Toshio Fukusato
Journal:  Hepatol Res       Date:  2014-04-24       Impact factor: 4.288

6.  Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Authors:  Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Science       Date:  2014-02-28       Impact factor: 47.728

7.  BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas.

Authors:  Kohei Fujikura; Takashi Yamasaki; Kyoko Otani; Maki Kanzawa; Takumi Fukumoto; Yonson Ku; Takanori Hirose; Tomoo Itoh; Yoh Zen
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

8.  Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.

Authors:  Daniel Baumhoer; Luigi Tornillo; Sylvia Stadlmann; Massimo Roncalli; Eva Karamitopoulou Diamantis; Luigi M Terracciano
Journal:  Am J Clin Pathol       Date:  2008-06       Impact factor: 2.493

9.  Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

Authors:  Jean-Charles Nault; Gabrielle Couchy; Charles Balabaud; Guillaume Morcrette; Stefano Caruso; Jean-Frederic Blanc; Yannick Bacq; Julien Calderaro; Valérie Paradis; Jeanne Ramos; Jean-Yves Scoazec; Viviane Gnemmi; Nathalie Sturm; Catherine Guettier; Monique Fabre; Eric Savier; Laurence Chiche; Philippe Labrune; Janick Selves; Dominique Wendum; Camilla Pilati; Alexis Laurent; Anne De Muret; Brigitte Le Bail; Sandra Rebouissou; Sandrine Imbeaud; Paulette Bioulac-Sage; Eric Letouzé; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2016-12-07       Impact factor: 22.682

10.  Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.

Authors:  Wanda M P Coston; Sofia Loera; Sean K Lau; Shin Ishizawa; Zhong Jiang; Chin-Lee Wu; Yun Yen; Lawrence M Weiss; Peiguo G Chu
Journal:  Am J Surg Pathol       Date:  2008-03       Impact factor: 6.394

View more
  5 in total

1.  Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations.

Authors:  Tiemo S Gerber; Lukas Müller; Fabian Bartsch; Lisa-Katharina Gröger; Mario Schindeldecker; Dirk A Ridder; Benjamin Goeppert; Markus Möhler; Christoph Dueber; Hauke Lang; Wilfried Roth; Roman Kloeckner; Beate K Straub
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

2.  SPOCK1 Promotes the Development of Hepatocellular Carcinoma.

Authors:  Lóránd Váncza; Katalin Karászi; Bálint Péterfia; Lilla Turiák; Katalin Dezső; Anna Sebestyén; Andrea Reszegi; Gábor Petővári; András Kiss; Zsuzsanna Schaff; Kornélia Baghy; Ilona Kovalszky
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

3.  Laboratory Profile of COVID-19 Patients with Hepatitis C-Related Liver Cirrhosis.

Authors:  Bianca Cerbu; Mirela Loredana Grigoras; Felix Bratosin; Iulia Bogdan; Cosmin Citu; Adrian Vasile Bota; Madalina Timircan; Melania Lavinia Bratu; Mihaela Codrina Levai; Iosif Marincu
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

4.  Ultrasomics prediction for cytokeratin 19 expression in hepatocellular carcinoma: A multicenter study.

Authors:  Linlin Zhang; Qinghua Qi; Qian Li; Shanshan Ren; Shunhua Liu; Bing Mao; Xin Li; Yuejin Wu; Lanling Yang; Luwen Liu; Yaqiong Li; Shaobo Duan; Lianzhong Zhang
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

5.  Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma.

Authors:  Maximilian Lennartz; Eva Gehrig; Sören Weidemann; Natalia Gorbokon; Anne Menz; Franziska Büscheck; Claudia Hube-Magg; Andrea Hinsch; Viktor Reiswich; Doris Höflmayer; Christoph Fraune; Frank Jacobsen; Christian Bernreuther; Patrick Lebok; Guido Sauter; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Andreas H Marx; Ronald Simon; Till Krech; Till S Clauditz; Sarah Minner; David Dum; Ria Uhlig
Journal:  Diagnostics (Basel)       Date:  2021-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.